SG11202107319PA - Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease - Google Patents
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune diseaseInfo
- Publication number
- SG11202107319PA SG11202107319PA SG11202107319PA SG11202107319PA SG11202107319PA SG 11202107319P A SG11202107319P A SG 11202107319PA SG 11202107319P A SG11202107319P A SG 11202107319PA SG 11202107319P A SG11202107319P A SG 11202107319PA SG 11202107319P A SG11202107319P A SG 11202107319PA
- Authority
- SG
- Singapore
- Prior art keywords
- autoantibody
- antibodies
- treatment
- pharmaceutical compositions
- autoimmune disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163036 | 2019-03-15 | ||
| PCT/EP2020/056757 WO2020187718A1 (en) | 2019-03-15 | 2020-03-13 | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107319PA true SG11202107319PA (en) | 2021-08-30 |
Family
ID=65817862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107319PA SG11202107319PA (en) | 2019-03-15 | 2020-03-13 | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144965A1 (en) |
| EP (1) | EP3938394A1 (en) |
| JP (1) | JP2022524204A (en) |
| KR (1) | KR20220002891A (en) |
| CN (1) | CN113574071A (en) |
| AU (1) | AU2020242228A1 (en) |
| CA (1) | CA3130132A1 (en) |
| IL (1) | IL286343A (en) |
| MX (1) | MX2021011181A (en) |
| SG (1) | SG11202107319PA (en) |
| TW (1) | TW202102541A (en) |
| WO (1) | WO2020187718A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022208200A1 (en) | 2021-01-14 | 2023-07-20 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| TW202302642A (en) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection |
| TW202321303A (en) * | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| CN1976950B (en) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | Anti-CD38 human antibodies and uses therefor. |
| SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| TWI428444B (en) * | 2005-10-12 | 2014-03-01 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| SI2081595T1 (en) | 2006-09-26 | 2019-10-30 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2009052293A1 (en) | 2007-10-16 | 2009-04-23 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| KR20130036276A (en) * | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Antibodies to the c3d fragment of complement component 3 |
| JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
| UA118255C2 (en) * | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
| BR112017024877A2 (en) * | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anti-cd38 antibody and its use in the treatment of light chain amyloidosis and other cd38 positive haematological malignancies |
| AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
-
2020
- 2020-03-13 WO PCT/EP2020/056757 patent/WO2020187718A1/en active Application Filing
- 2020-03-13 KR KR1020217032828A patent/KR20220002891A/en unknown
- 2020-03-13 CA CA3130132A patent/CA3130132A1/en active Pending
- 2020-03-13 CN CN202080021080.2A patent/CN113574071A/en active Pending
- 2020-03-13 US US17/434,465 patent/US20220144965A1/en active Pending
- 2020-03-13 TW TW109108366A patent/TW202102541A/en unknown
- 2020-03-13 JP JP2021554758A patent/JP2022524204A/en active Pending
- 2020-03-13 EP EP20711164.2A patent/EP3938394A1/en active Pending
- 2020-03-13 AU AU2020242228A patent/AU2020242228A1/en active Pending
- 2020-03-13 MX MX2021011181A patent/MX2021011181A/en unknown
- 2020-03-13 SG SG11202107319PA patent/SG11202107319PA/en unknown
-
2021
- 2021-09-13 IL IL286343A patent/IL286343A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3938394A1 (en) | 2022-01-19 |
| CA3130132A1 (en) | 2020-09-24 |
| TW202102541A (en) | 2021-01-16 |
| WO2020187718A1 (en) | 2020-09-24 |
| US20220144965A1 (en) | 2022-05-12 |
| AU2020242228A1 (en) | 2021-07-22 |
| IL286343A (en) | 2021-10-31 |
| MX2021011181A (en) | 2022-01-19 |
| KR20220002891A (en) | 2022-01-07 |
| CN113574071A (en) | 2021-10-29 |
| JP2022524204A (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL286343A (en) | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease | |
| WO2017049038A3 (en) | Anti-cd115 antibodies | |
| EP3807270C0 (en) | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | |
| IL288375A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL268007A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
| IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL279622A (en) | Pharmaceutical formulations of masked antibodies | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL274007A (en) | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same | |
| EP3740592A4 (en) | Methods and compositions for the treatment of vascular disease | |
| IL287477A (en) | Anti-cd38 antibodies and formulations | |
| IL285751A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HUE053866T2 (en) | Pharmaceutical composition for the treatment of constipation | |
| GB201803563D0 (en) | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201809836D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL287392A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| EP3732204A4 (en) | Anti-renalase antibodies for the treatment and prevention of diseases and disorders | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| IL285297A (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
| GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL289734A (en) | Compositions and methods for the treatment of sanfilippo disease and other disorders |